Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep:136:102244.
doi: 10.1016/j.tube.2022.102244. Epub 2022 Aug 11.

Immunologic and imaging signatures in post tuberculosis lung disease

S Singh  1 , B W Allwood  2 , T L Chiyaka  3 , L Kleyhans  4 , C C Naidoo  5 , S Moodley  6 , G Theron  7 , L N Segal  8
Affiliations
Review

Immunologic and imaging signatures in post tuberculosis lung disease

S Singh et al. Tuberculosis (Edinb). 2022 Sep.

Abstract

Post Tuberculosis Lung Disease (PTLD) affects millions of tuberculosis survivors and is a global health burden. The immune mechanisms that drive PTLD are complex and have historically been under investigated. Here, we discuss two immune-mediated paradigms that could drive human PTLD. We review the characteristics of a fibrotic granuloma that favors the development of PTLD via an abundance of T-helper-2 and T-regulatory cells and an upregulation of TGF-β mediated collagen deposition. Next, we discuss the post-primary tuberculosis paradigm and the complex mixture of caseous pneumonia, cavity formation and fibrosis that can also lead to PTLD. We review the delicate balance between cellular subsets and cytokines of the innate and adaptive immune system in conjunction with host-derived proteases that can perpetuate the parenchymal lung damage seen in PTLD. Next, we discuss the role of novel host directed therapies (HDT) to limit the development of PTLD and in particular, the recent repurposing of established medications such as statins, metformin and doxycycline. Finally, we review the emerging role of novel imaging techniques as a non-invasive modality for the early recognition of PTLD. While access to computed tomography imaging is unlikely to be available widely in countries with a high TB burden, its use in research settings can help phenotype PTLD. Due to a lack of disease-specific biomarkers and controlled clinical trials, there are currently no evidence-based recommendations for the management of PTLD. It is likely that an integrated antifibrotic strategy that could simultaneously target inflammatory and pro-fibrotic pathways will probably emerge as a successful way to treat this complex condition. In a disease spectrum as wide as PTLD, a single immunologic or radiographic marker may not be sufficient and a combination is more likely to be a successful surrogate that could aid in the development of successful HDTs.

Keywords: Biomarker; Granuloma; Host directed therapy; Imaging; PTLD; Radiographic signature.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Depicts the characteristics of a fibrotic granuloma (left) and a transmissive granuloma (right). Fibrotic granulomas have an abundance of Th2 and Treg cells that drive TGF-β mediated collagen deposition, thick capsule consisting of myofibroblasts and an abnormal fibrous cuff. Transmissive granulomas are rich in classically activated and foamy macrophages as well as neutrophils. These cells produce inflammatory mediators such as tumor necrosis factor (TNF)-α and matrix metalloproteinases (MMPs) and depending on other host modulating factors, can result in the development of active cavitary TB disease. As the figure depicts, fibrotic granulomas favor the development of PTLD and transmissive granulomas favor the development of active TB, but granulomas can undergo changes driven by host factors and surrounding milieu such that they can morph into one or the other kind. Finally, the figure also depicts that active cavitary TB can lead to PTLD in the event of aberrant healing and distortion of lung architecture.
Fig. 2.
Fig. 2.
An overview of the various HDTs that are undergoing clinical trials, such as PDE4 inhibitors, cellular and cytokine targets, repurposed drugs and RNA interference technology. Here we focus on HDTs that can potentially be used for individuals that are at high risk of developing PTLD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Organisation WH. Global tuberculosis report. 2021.
    1. Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis 2021;21(7):984–92. - PubMed
    1. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Global Health 2021;9(12):e1679–87. - PMC - PubMed
    1. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003;3(5):282–7. - PubMed
    1. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019;19(10):1129–37. - PubMed

Publication types

MeSH terms